| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/01/2023 | 2.43% | Goldman Sachs | $27 → $24 | Maintains | Neutral |
| 10/17/2023 | 10.97% | Truist Securities | $31 → $26 | Maintains | Hold |
| 08/02/2023 | 32.31% | Truist Securities | $35 → $31 | Maintains | Hold |
| 04/11/2023 | 45.11% | Goldman Sachs | $39 → $34 | Downgrades | Buy → Neutral |
| 02/08/2023 | -10.37% | Piper Sandler | $24 → $21 | Maintains | Underweight |
| 12/12/2022 | 2.43% | Piper Sandler | $31 → $24 | Downgrades | Neutral → Underweight |
| 10/12/2022 | 70.72% | Goldman Sachs | $45 → $40 | Maintains | Buy |
| 06/23/2022 | 83.53% | Goldman Sachs | $50 → $43 | Maintains | Buy |
| 06/14/2022 | 53.65% | Piper Sandler | $40 → $36 | Maintains | Neutral |
| 05/04/2022 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 04/07/2022 | 62.19% | Piper Sandler | $43 → $38 | Maintains | Neutral |
| 02/09/2022 | 113.4% | Raymond James | $55 → $50 | Maintains | Outperform |
| 11/03/2021 | 134.74% | Raymond James | $60 → $55 | Maintains | Outperform |
| 05/05/2021 | 156.08% | Raymond James | $48 → $60 | Maintains | Outperform |
| 02/10/2021 | — | Raymond James | Downgrades | Strong Buy → Outperform | |
| 11/20/2020 | 121.94% | Goldman Sachs | → $52 | Upgrades | Neutral → Buy |
| 11/04/2020 | 79.26% | Piper Sandler | $39 → $42 | Maintains | Neutral |
| 11/04/2020 | 104.87% | Raymond James | $45 → $48 | Maintains | Strong Buy |
| 08/05/2020 | 92.06% | Raymond James | $41 → $45 | Maintains | Strong Buy |
| 07/28/2020 | 74.99% | Raymond James | $38 → $41 | Maintains | Strong Buy |
| 05/28/2020 | 62.19% | Raymond James | $32 → $38 | Maintains | Strong Buy |
| 05/18/2020 | 28.04% | SunTrust Robinson Humphrey | $27 → $30 | Maintains | Hold |
| 05/14/2020 | 36.58% | Raymond James | → $32 | Upgrades | Market Perform → Strong Buy |
| 05/06/2020 | 15.24% | SunTrust Robinson Humphrey | $29 → $27 | Maintains | Hold |
| 04/16/2020 | 23.77% | SunTrust Robinson Humphrey | $24 → $29 | Maintains | Hold |
| 04/15/2020 | 49.38% | Piper Sandler | $47 → $35 | Maintains | Neutral |
| 04/03/2020 | 2.43% | SunTrust Robinson Humphrey | $50 → $24 | Maintains | Hold |
| 11/19/2019 | 134.74% | Stifel | $52 → $55 | Downgrades | Buy → Hold |
| 10/30/2019 | — | SunTrust Robinson Humphrey | Downgrades | Buy → Hold | |
| 07/24/2019 | — | Raymond James | Downgrades | Outperform → Market Perform |
What is the target price for Leggett & Platt (LEG)?
The latest price target for Leggett & Platt (NYSE: LEG) was reported by Goldman Sachs on November 1, 2023. The analyst firm set a price target for $24.00 expecting LEG to rise to within 12 months (a possible 2.43% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Leggett & Platt (LEG)?
The latest analyst rating for Leggett & Platt (NYSE: LEG) was provided by Goldman Sachs, and Leggett & Platt maintained their neutral rating.
When is the next analyst rating going to be posted or updated for Leggett & Platt (LEG)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Leggett & Platt, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Leggett & Platt was filed on November 1, 2023 so you should expect the next rating to be made available sometime around November 1, 2024.
Is the Analyst Rating Leggett & Platt (LEG) correct?
While ratings are subjective and will change, the latest Leggett & Platt (LEG) rating was a maintained with a price target of $27.00 to $24.00. The current price Leggett & Platt (LEG) is trading at is $23.43, which is out of the analyst's predicted range.